LSTA logo

Lisata Therapeutics, Inc. Stock Price

NasdaqCM:LSTA Community·US$21.3m Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author
Create a narrative

LSTA Share Price Performance

US$2.37
-0.61 (-20.47%)
92.6% undervalued intrinsic discount
US$32.00
Fair Value
US$2.37
-0.61 (-20.47%)
92.6% undervalued intrinsic discount
US$32.00
Fair Value
Price US$2.37
AnalystHighTarget US$32.00
AnalystConsensusTarget US$20.67

LSTA Community Narratives

AnalystHighTarget·
Fair Value US$32 92.1% undervalued intrinsic discount

Breakthrough Trials And Global Trends Will Redefine Oncology

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$20.67 87.8% undervalued intrinsic discount

Positive Clinical Trials Will Expand Precision Oncology Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Recent LSTA News & Updates

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

Aug 13
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

We Think Lisata Therapeutics (NASDAQ:LSTA) Needs To Drive Business Growth Carefully

Apr 26
We Think Lisata Therapeutics (NASDAQ:LSTA) Needs To Drive Business Growth Carefully
User avatar

Certepetide Advancements And Regulatory Approvals Will Set New Care Standards

Advancements in certepetide and regulatory achievements could expedite market entry, fostering revenue growth and enhancing treatment standards.

Lisata Therapeutics, Inc. Key Details

US$1.1m

Revenue

US$0

Cost of Revenue

US$1.1m

Gross Profit

US$20.0m

Other Expenses

-US$18.9m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-2.16
Gross Margin
100.00%
Net Profit Margin
-1,768.50%
Debt/Equity Ratio
0%

Lisata Therapeutics, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks
1 Reward
View Full Analysis

About LSTA

Founded
1980
Employees
26
CEO
David Mazzo
WebsiteView website
www.lisata.com

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Market Insight

Header cover image

📈 Markets Break Records: Q3 2025 in Review, Q4 Outlook Ahead

Richard Bowman avatarRichard Bowman
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Last Week
✨Rare Earths: Tiny Market, Outsized Influence

✨Rare Earths: Tiny Market, Outsized Influence

U.S. Market Performance

  • 7 Days: 0.3%
  • 3 Months: 8.5%
  • 1 Year: 17.3%
  • Year to Date: 15.0%
In the last week, the market has been flat. Meanwhile, the market is actually up 17% over the past year. Earnings are forecast to grow by 15% annually. Market details ›